SAN FRANCISCO — Oura has delayed its initial public offering. The health technology company cited uncertainty in the IPO market as the reason for the delay.

The decision comes despite strong demand for the company's shares and robust financial performance. Oura stated the delay occurred despite strong demand, positioning the move as a strategic choice rather than a reaction to weak interest.

Oura formally launched its IPO plans on September 21, 2026. The company planned to raise up to $2.2 billion by selling 50 million shares. The IPO was expected to value Oura at approximately $15 billion if shares sold at the top of the price range. Oura planned to begin trading on the Nasdaq under the ticker symbol OURA.

Oura reported growth in its user base and revenue leading up to the planned listing. The company has 5 million paying members. Oura's number of paying members doubled from 2024 to 2025 and again in 2026.

Financial disclosures showed a 74% increase in revenue from 2024 to 2025. Oura expects revenue for the fiscal year ending September 2026 to have grown by 90%. The company reported a net profit of nearly $61 million between October 2025 and June 2026.

Product sales contributed to this financial expansion. Oura sold 3.6 million rings between mid-2025 and mid-2026. Oura rings cost between $350 and $500.

In addition to hardware sales, Oura charges a $6 monthly subscription fee for access to most data and personalized health insights. Oura states its rings track more than 50 health metrics, including heart rate, body temperature, stress levels, and sleep patterns. Oura states it has collected nearly 42 billion hours of physiological data since its founding.

Market analysts pointed to broader economic conditions as a factor in the timing of the delay. Renaissance Capital stated that concerns about a slowdown in AI spending, Federal Reserve rate hikes, and rising bond yields contributed to the IPO market tailing off in the third quarter. The U.S. IPO market saw a 35% decline in deals in the third quarter of 2026 compared to the same period in 2025, indicating broader market uncertainty that may have contributed to Oura's decision to delay its listing.

"Oura's success is as much about this hardware aspect as it is about the subscription model and the revenue that comes from that," analyst Arielle Trzcinski said. She noted the high engagement levels among users. "The fact that folks not only start wearing it and become paying members, but also that they wear it roughly five days a week, which is significant," Trzcinski said.

The company faces legal challenges alongside its growth. A class-action lawsuit alleges Oura misled users about the quality of its sleep tracking. Oura disputes the allegations in the class-action lawsuit.

For approximately one-third of Oura's new customers, the ring is their first wearable device. Celebrities Lady Gaga and Coco Gauff wear Oura rings. Oura was founded in Finland in 2013. Oura is based in San Francisco.

Why It Matters

There is no prior precedent of a company postponing its Nasdaq listing despite strong financial growth and a doubling of paying members, making Oura's decision an unusual move in the current IPO market landscape. The combination of strong internal metrics and external market hesitation shows the complex environment companies face when going public.

The broader decline in IPO activity suggests that macroeconomic factors are influencing corporate decisions beyond individual company performance. With the U.S. IPO market seeing a 35% decline in deals in the third quarter of 2026 compared to the same period in 2025, Oura's choice reflects a cautious approach shared by other firms navigating similar uncertainties.

Timeline

Oura was founded in Finland in 2013.

Oura cited uncertainty in the IPO market as the reason for the delay. Oura stated the delay occurred despite strong demand. CEO Tom Hale issued statements on September 28, 2026, regarding the decision. "Our mission is to empower people to live healthier, longer, and an IPO is just one step in our journey," Hale said. "We aim to deliver an extraordinary IPO for our employees and investors and we have the luxury of choosing our moment," he said. "In the meantime, we will execute against the opportunities ahead," he said.

What's New

Additional reporting indicates there is no prior precedent of a company postponing its Nasdaq listing despite strong financial growth and a doubling of paying members, making Oura's decision an unusual move in the current IPO market landscape. Further data shows the U.S. IPO market saw a 35% decline in deals in the third quarter of 2026 compared to the same period in 2025, indicating broader market uncertainty that may have contributed to Oura's decision to delay its listing. Additional details confirm Oura formally launched its IPO plans on September 21, 2026. Reports also state Oura expects revenue for the fiscal year ending September 2026 to have grown by 90%. CEO Tom Hale provided further context on the delay, stating, "Our mission is to empower people to live healthier, longer, and an IPO is just one step in our journey." He also said, "We aim to deliver an extraordinary IPO for our employees and investors and we have the luxury of choosing our moment." He added, "In the meantime, we will execute against the opportunities ahead."